Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-070900
Filing Date
2025-05-14
Accepted
2025-05-14 07:03:05
Documents
82
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q spry-20250331.htm   iXBRL 10-Q 2482150
2 EX-10.1 spry-ex10_1.htm EX-10.1 23529
3 EX-31.1 spry-ex31_1.htm EX-31.1 16749
4 EX-31.2 spry-ex31_2.htm EX-31.2 16723
5 EX-32.1 spry-ex32_1.htm EX-32.1 20978
6 GRAPHIC img77823595_0.jpg GRAPHIC 484952
  Complete submission text file 0000950170-25-070900.txt   10893927

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT spry-20250331.xsd EX-101.SCH 1294728
85 EXTRACTED XBRL INSTANCE DOCUMENT spry-20250331_htm.xml XML 1577338
Mailing Address 11682 EL CAMINO REAL, SUITE 120 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL, SUITE 120 SAN DIEGO CA 92130 858-771-9307
ARS Pharmaceuticals, Inc. (Filer) CIK: 0001671858 (see all company filings)

EIN.: 811489190 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39756 | Film No.: 25942595
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)